Spermosens (SPERM) Q1 2025 earnings summary

Executive summary

• Achieved positive interim results in ongoing clinical study, validating JUNO-Checked technology for fertility diagnostics.

• Secured SEK 10.8 million in strategic investment, ensuring funding through mid-2026 and supporting clinical and commercial milestones.

• Advanced commercial strategy focused on licensing and partnerships in Europe, US, and Japan, with potential agreements expected in H2 2026.

• Appointed Dr. Jaime Castillo-León as CTO and entered strategic collaboration with Scalania AG to accelerate development.

Financial highlights

• Net sales for Q1 2025 were SEK 0 thousand, unchanged year-over-year.

• Operating loss for Q1 2025 was SEK -2,063 thousand, an improvement from SEK -2,604 thousand in Q1 2024.

• Cash and cash equivalents at period end were SEK 2,118 thousand, down from SEK 4,492 thousand at year-end 2024.

• Equity at period end was SEK 38,100 thousand, up from SEK 8,820 thousand in Q1 2024, reflecting new capital raised.

• Earnings per share for Q1 2025 were SEK -0.002, compared to SEK -0.078 in Q1 2024.

Outlook and guidance

• Funding secured through mid-2026 enables completion of clinical study and further technology optimization.

• Realistic expectation to enter partnership and license agreements in H2 2026 based on ongoing discussions and clinical progress.

• Focus remains on completing clinical study, improving JUNO-Checked, and advancing commercialization strategy.